CGL Spectrum Community Pharmacy Commissioned Services
**IMPORTANT COVID-19 UPDATE** 23 April 2020
Please see below an update from CGL.
Help by saving lives and reducing risk to IV users!
During this unprecedented time you are ideally placed for providing Needle and Syringe Service and Take-Home Naloxone to the target at-risk population who need it most.
You will all be aware of the impact coronavirus is having on our families, communities and society. Providing service users who inject drugs clean needles and syringes simultaneously and a Take-Home Naloxone Kit to those injecting and at risk of opiate overdose will assist towards protecting their health until they are ready and willing to cease injecting and ultimately achieve a drug-free life with the appropriate support.
We therefore would like to remind all Pharmacies who are part of the Needle and Syringe Scheme to please make sure that you are well stocked for both needle packs and Naloxone Take Home. Please actively promote the uptake of Naloxone Take Home with service users or their carers.
A reminder that to order stock please use your usual method through Frontier Medical and order enough to give out packs to allow the service user to have clean equipment for at least 14 days.
Each pharmacy on the scheme should also have in stock five Take Home Naloxone kits and maintain a stock of five kits throughout. In other words, with every kit issued, this must be replaced. These are replaced by ordering via Alliance Healthcare or Frontier Medical Supplies by telephone, email or fax.
We have included the link to a 3 minute Take Home Naloxone Training video that can help in informing the service user/carer what Naloxone is, where is it and how to use the kit.
If you need any support in ordering or how to encourage service users to take a Naloxone kit please get in contact with Trudy Sealy on 07881 335213.
Finally, thank you for your continued support. To contact us please telephone 0800 652 3169 or email us on email@example.com
Deputy Services Manager of East Cluster, North Cluster and Volunteering
Hertfordshire EDI and NSP Lead
The LPC has had no input to the communication and does not endorse the clinical decision that has been made to issue 14-day prescriptions. This decision was made without consultation with the LPC.
During the current period, the LPC encourages those with service users to ensure you:
- have contact numbers for all service users;
- have communicated with CGL how they can contact you easily in an emergency; and
- be aware that CGL staff or possibly couriers will deliver the prescriptions to the pharmacy and would be grateful if you could aim not to make them wait long periods of time although recognise your current workload.
CGL (previously CRI) Spectrum are commissioned to provide drugs and alcohol services within Hertfordshire by Hertfordshire County Council and they subcontract supervised consumption and needle exchange services from some community pharmacies.
The Service Level Agreement for Supervised Consumption Programme and Pharmacy Needle & Syringe Programme has been revised and comes into effect on 01 September 2019 as detailed in a letter from CGL Spectrum in August 2019.
If you would like to sign up for any service and have any queries regarding a service you can contact CGL Spectrum via their countywide email Herts@cgl.org.uk
CGL Spectrum launched their new All Ages Drug and Alcohol Service, on 1 April 2019. They now deliver support for both adults and under-18s and have created a dedicated website detailing some of the changes and improvements.
Supervised Consumption Service
The supervised consumption programme in Hertfordshire is commissioned by CGL Spectum.
The 2019 Service Level Agreement (SLA) for community pharmacists providing supervised consumption of medication can be accessed here.
Needle Exchange Service
The needle exchange service provided by community pharmacy is commissioned by CGL Spectrum.
The 2019 Service Level Agreement (SLA) for community pharmacists providing needle exchange incorporating take home Naloxone can be accessed here.
CGL Spectrum Pharmacy Newsletters
January 2019 – Pharmacy Newsletter – issue 3
July 2018 – Pharmacy Newsletter – issue 2
December 2018 – Pharmacy Newsletter – quarterly briefing
January 2018 – Pharmacy Newsletter – issue 1
July 2017 – Pharmacy Newsletter – quarterly briefing
August 2017 Pharmacy Newsletter – quarterly briefing
CGL Spectrum Medicine Update and Changes
October 2019 CGL Spectrum – Requests to void supervised consumption prescriptions
A new measure has been introduced by CGL Spectrum that is intended to lessen, or best avoid dispensing against voided prescriptions which is an error that does occur due to systemic errors. Full information on the process change is contained within the letter that has also been circulated via PharmOutcomes and with every batch envelope over the next four weeks.
February 2019 – Prescription change from generic buprenorphine to Espranor® (buprenorphine oral lyophilisate) 2mg and 8mg. Further details here
February 2019 – CGL Spectrum reminder letter that Espranor is not interchangeable with generic buprenorphine sublingual tablets at the same dose. Further information can be obtained from http://www.medicines.org.uk.
Please inform CGL Spectrum if you have been involved in any incidents involving Espranor / Buprenorphine in the usual way and in your normal CD reporting processes.
December 2018 – CGL Spectrum provided a bulletin with FAQ’s included around the changes from buprenorphine tablets to Espranor.
May 2016 – CGL Spectrum letter to pharmacies around the switch of methadone solution 1mg/ml to Physeptone® oral solution 1mg/ml and Physeptone® oral solution sugar free 1mg/ml.